Bio-Techne Corp
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +40.0% | -2.6% | -6.8% | -15.4% | +32.0% | -51.2% | +138.8% | -71.9% | +198.8% | +5.2% | +10.1% | – | |
| – | -2.6% | -1.8% | +2.7% | +0.3% | -3.7% | +1.8% | -1.7% | -10.2% | +1.5% | -2.2% | -0.1% | – | |
| – | +158.0% | -68.8% | -13.2% | +44.2% | +44.4% | -22.6% | -60.1% | +156.7% | +19.5% | -24.8% | -50.2% | – | |
| – | +794.5% | -92.9% | -869.0% | – | – | -202.4% | – | -298.7% | – | -109.6% | – | – | |
| – | +9.4% | +10.6% | +9.4% | -49.0% | -25.6% | +48.4% | -51.7% | +9.7% | +10.4% | +53.5% | -6.7% | – | |
| – | -84.6% | -30.5% | -46.4% | +146.2% | -76.8% | +76.3% | – | +49.0% | -1,078.7% | -1.8% | +21.3% | – | |
| – | -0.8% | +0.2% | +0.4% | +0.5% | +0.4% | -1.2% | -1.5% | +0.5% | +0.2% | +0.4% | -0.3% | – | |
| – | +295.7% | -99.8% | +139.3% | – | – | +32.3% | +0.0% | -100.0% | +0.0% | – | -173,819.6% | – | |
| – | – | – | – | – | -100.0% | – | -46.7% | -387.5% | -13.0% | +50.0% | -100.0% | – | |
| – | -213.8% | -35.6% | +14.7% | -80.7% | +624.5% | -18.8% | +32.9% | -51.1% | +10.8% | -12.8% | -22.3% | – | |
| – | – | – | +21.4% | +201.0% | -127.9% | – | – | -180.1% | – | +32.3% | +48.6% | – | |
| – | +49.1% | -5.4% | -10.9% | -4.9% | +41.7% | -60.0% | +201.0% | -76.2% | +244.2% | +1.4% | +12.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.